secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amesite Inc. (AMST)
CIK:        0001807166
Form:       8-K
Filed at:   2021-12-21T23:59:59+00:00
Accession:  0001213900-21-066698
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amesite terminates CFO Matthew Kern, appoints Mark Corrao as CFO effective Dec 15, 2021
--------------------------------------------------------------------------------

- Matthew Kern terminated as CFO on Dec 15, 2021; Mark Corrao appointed same day.
- Corrao serves as non-employee, part-time CFO; compensation $3,000 signing + $3,000/month.
- Corrao is also CFO of Neuropathix and former CFO of Generex Biotechnology and Brain Scientific.
- Agreement includes indemnification and D&O insurance; term is one year, extendable by mutual consent.
- Corrao remains independent CFO; company also retains The CFO Squad LLC for pre-audit and SEC compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807166/000121390021066698/0001213900-21-066698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807166/000121390021066698/ea152831-8k_amesite.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-066698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer